Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis

@article{Mehta2019TargetingMD,
  title={Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis},
  author={A. Mehta and Rachel Walters and Fergal M. Waldron and S. Pal and Bhuvaneish T. Selvaraj and M. Macleod and G. Hardingham and S. Chandran and J. M. Gregory},
  journal={Brain Communications},
  year={2019},
  volume={1}
}
Abstract Interventions targeting mitochondrial dysfunction have the potential to extend survival in preclinical models of amyotrophic lateral sclerosis. The aim of this systematic review was to assess the efficacy of targeting mitochondria as a potential therapeutic target in amyotrophic lateral sclerosis. Preclinical studies written in the English language were identified with no restrictions on publication date from PubMed, Medline and EMBASE databases. All studies adopting interventions… Expand

Figures and Topics from this paper

References

SHOWING 1-10 OF 76 REFERENCES
Mitochondrial dysfunction in amyotrophic lateral sclerosis.
Mitochondrial dysfunction in ALS
Miro1 deficiency in amyotrophic lateral sclerosis
mTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases.
Amyotrophic lateral sclerosis.
A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.
Modelling amyotrophic lateral sclerosis: progress and possibilities
...
1
2
3
4
5
...